報價延遲最少15分鐘:2026/04/21 23:58 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.02 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.29/-0.62
|
|
企業價值
30.62M
|
| 資產負債 |
|
每股賬面淨值
0.19
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.20M
|
|
每股收益
0.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs. |
